Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2001-09-27
2009-08-04
Andes, Janet L. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
Reexamination Certificate
active
07569724
ABSTRACT:
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)— and —C(═O)NR1-; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
REFERENCES:
patent: 5369108 (1994-11-01), Breslow
patent: 5700811 (1997-12-01), Breslow
patent: 5804601 (1998-09-01), Kato
patent: 5834249 (1998-11-01), Furukawa
patent: 6225311 (2001-05-01), Levin et al.
patent: 0 301 861 (1989-02-01), None
patent: 0 827 742 (1998-03-01), None
patent: 10-114681 (1998-05-01), None
patent: 10-182583 (1998-07-01), None
patent: WO 93/12075 (1993-06-01), None
patent: WO 95/31977 (1995-11-01), None
patent: 98/26773 (1998-06-01), None
patent: WO 98/55449 (1998-12-01), None
patent: WO 00/21979 (2000-04-01), None
patent: 00/44709 (2000-08-01), None
patent: 00/44713 (2000-08-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 02/22577 (2002-03-01), None
Jung et al; “Analogues of Trichostatin A and Trapoxin B as Histone Deacetylase Inhibitors”; Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 7, No. 13, Jul. 8, 1997, pp. 1655-1658, XP004136274.
Schmidt et al; “Inhibitors of Histone Deacetylase Suppress the Growth of MCF-7 Breast Cancer Cells”; Archiv DER Pharmazie, VCH Verlagsgesellschaft MBH, Weinheim, DE, vol. 332, No. 10, 1999, pp. 353-357, XP000985303.
Jung et al; “Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation”; Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 42, NO. 22, Nov. 4, 1999, pp. 4669-4679, XP002144226.
Andrews et al., 2000, “Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents”Int. J. Parasitol., vol.30, No. 6, pp. 761-768.
Anghelova, Y. et al, 1973, “Kondensation, der Äthylester von Croton-, 3-Methylcroton- und Isopropylidenmalonsäure mit aromatischen Aldehyden”Chem. Ber., vol. 106, p. 2643.
Backer, H.J., et al., 1940, “Condensation de la benzile avec les acides oxy-, thio, et sélénodiacetiques”Recl. Trav. Chim. Pays-Bas, vol. 59, p. 423.
Banerji, A., et al., 1984, “Substituent effects on carbon-13 NMR chemical shifts of side-chain carbons in 5-aryl-2E,4E-pentadienoic acid derivatives”Indian J. Chem., vol. 23B, pp. 546-549.
Bellamy, F.D., et al., 1984, “Selective reduction of aromatic nitro compounds with stannous chloride in non-acidic and non-aqueous medium.”Tetrahedron Letters, vol. 25, No. 8, p. 839.
Bernhard, D. et al., 1999, “Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts,”FASEB J., vol. 13, No. 14, pp. 1991-2001.
Bernstein et al., 2000, “Genomewide studies of histone deacetylase function in yeast.”Proc. Natl. Acad. Sci. USA, vol. 97, No. 25, pp. 13708-13713.
Bistrzycki A et al 1912, “Die Konstitution der Verbindungen aus o-Diaminen and □-Oxysäuren”Chem. Ber., vol. 45, p. 3483.
Brehm, A., et al., 1998, “Retinoblastoma protein recruits histone deacetylase to repress transcription,”Nature, 1998, vol. 391, pp. 597-601.
Carbonnier, J., et al., 1981, “Activité antitranspirante d'analogues de l'acide abscissique”Physiol. Plant., 1981, vol. 51, p. 1.
Chang et al., 2000, “Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.”Nucleic Acids Res., vol. 28, No. 20, pp. 3918-3925.
Chen, W.-S., et al., 1978,“ Ambivalent active-site-directed inactivators of liver alcohol dehydrogenase.”Biochemistry, vol. 17, No. 23, p. 4916.
Copeland, R.A.B., et al., 1943, The Preparation and Reactions of 2-Benzimidazolecarboxylic Acid and 2-Benzimidazoleacetic AcidJ. Amer. Chem. Soc., vol. 65, p. 1072.
Dangond et al., 1998, “Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells.”Biochem. Biophys. Res. Commun., vol. 242, No. 3, pp. 648-652.
David, G., et al., 1998, “Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukaemia-associated PLZF protein.”Oncogene, vol. 16(19), pp. 2549-2556.
Davie, J.R., 1998, “Covalent modifications of histones: expression from chromatic templates,”Curr. Opin. Genet. Dev., vol. 8, pp. 173-178.
Desai, D et al., 1999, “Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(-methylnitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice.”Proc. AACR, vol. 40, abstract #2396.
Emiliani, S., et al., 1998, “Characterization of a human RPD3 ortholog, HDAC3,”Proc. Natl. Acad. Sci. USA, vol. 95, p. 2795-2800.
Finnin et al., 1999, “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.”Nature, vol. 401, pp. 188-193.
Glick, R.D., et al., 1999, “Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma,”Cancer Research, vol. 59, No. 17, pp. 4392-4399.
Grozinger et al., 1999, “Three proteins define a class of human histone deacetylases related to yeast Hda1p.”Proc. Natl. Acad. Sci. USA, vol. 96, pp. 4868-4873.
Hoshikawa, Y., et al., 1994, “Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.”Exp. Cell. Res., vol. 214(1), pp. 189-197.
Jung et al., 1997, “Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors”Bioorg. Med. Chem. Lett., vol. 7, No. 13, pp. 1655-1658.
Jung et al., 1999, “Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.”J. Med. Chem., vol. 42, pp. 4669-4679.
Kao et al., 2000, “Isolation of a novel histone deacetylase reveals that class I and class II deactylases promote SMRT-mediated repression”Genes Dev., vol. 14, p. 55-66.
Kijima et al., 1993, “Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.”J. Biol. Chem., vol. 268, pp. 22429-22435.
Howe, L., et al., 1999, “Histone acetyltransferase complexes and their link to transcription”Crit. Rev. Eukaryot. Gene Expr., vol. 9(3-4), pp. 231-243.
Iavarone et al., 1999, “E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest.”Mol. Cell Biol., vol. 19, No. 1, pp. 916-922.
Kim, M.S., et al., 2001 “Histone deacetylase induce angiogenesis by negative regulation of tumour suppressor genes,”Nature Medicine, vol. 7. No. 4 pp. 437-443.
Kimura et al., 1994, “Dual modes of action of platelet-derived growth factor and its inhibition by trichostatin-A for DNA synthesis in primary cultured smooth muscle cells of rat aorta”.Biol. Pharm. Bull., vol. 17, No. 3, pp. 399-402.
Kitamura, K., et al., 2000, Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acidBr. J. Haematol., vol. 108(4), pp. 696-702.
Kouzarides, T., 1999, “Histone acetylases and deacetylase in cell proliferation
Amolins Andris
Andrianov Victor
Bokaldere Rasma M
Dikovska Klara
Duffy James E. S.
Andes Janet L.
Covington Raymond
Nixon & Vanderhye P.C.
Topotarget UK Limited
LandOfFree
Carbamic acid compounds comprising an amide linkage as HDAC... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamic acid compounds comprising an amide linkage as HDAC..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamic acid compounds comprising an amide linkage as HDAC... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4132368